Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Investor's Business Daily on MSN3h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback